Today's Rundown La Jolla stops pivotal trial, parts company with CEO CymaBay plummets 75% as it axes liver studies in NASH, PBC Teva forms academic R&D pacts to further biopharma strategy [Sponsored] How life sciences brands can win on mobile, right now In conversation with Darren Kelly, CEO of Certa Therapeutics and OccuRx Attacking drug-resistant infections by exploiting bacterial weak spots AstraZeneca teams up with Novoheart for 'heart-in-a-jar' Featured Story | | | Tuesday, November 26, 2019 La Jolla Pharmaceutical has stopped a pivotal trial of LJPC-401 after an interim review. The company disclosed the setback on the same day it revealed its CEO and president George Tidmarsh has left “to pursue other interests.” |
|
|---|
|
Top Stories Monday, November 25, 2019 CymaBay Therapeutics is pulling the plug on two midphase studies of its liver drug and putting all other studies of the drug on hold after biopsies found liver damage in some patients. The company’s stock nose-dived more than 75% Monday. Tuesday, November 26, 2019 Teva has entered into a pair of research collaborations with Israeli institutions. The Israeli pharma will support work on anti-cancer antibodies at the Weizmann Institute of Science while collaborating with Tel Aviv University on oncology and brain studies. Monday, November 25, 2019 Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story. Tuesday, November 26, 2019 At first glance, Darren Kelly doesn’t seem to sleep. He’s the CEO of not one but two fibrosis-related biotechs, an entrepreneur in residence at Australia’s largest life sciences-focused VC firm, a director at the Centre for Eye Research Australia and—to top it all off—the associate dean of innovation and enterprise at the University of Melbourne. Monday, November 25, 2019 The world’s most vexing infectious bacteria are quickly becoming resistant to available antibiotics. Now, two research teams are proposing entirely new methods for attacking these bugs, not by killing them directly but rather by taking advantage of structural weaknesses in ways that make it impossible for the bacteria to survive. Tuesday, November 26, 2019 We know about organs-on-a-chip; now, Big Pharma AstraZeneca is working with Canadian stem cell biotech Novoheart to develop a first-of-its-kind heart-in-a-jar. Enrollment Showcase | | | Sponsored by: University of Florida College of Pharmacy University of Florida precision medicine leaders highlight current knowledge and trends to advance the future of health care in this new webinar series. Register today. |
|
|---|
|
Resources Sponsored by: Catalent Pharma Solutions In this Q&A, four Catalent Biologics experts share how scale-up, regulatory expectations, demand forecasting and process validation all play a role in the success of a biologic when embarking upon the commercial manufacturing journey. Sponsored by: Amazon Web Services From IoT to data management to high-performance computing and machine learning, leading life sciences organizations are using Amazon Web Services (AWS) to develop scalable, global, predictable, and secure solutions to modernize clinical trials while mitigating risks Sponsored by: Outer Edge Technology, LLC See why visionaries outsource the design and management of the infrastructure allowing their scientists to innovate. Sponsored by: Veeva Systems Medical Affairs 2025 brings together leading perspectives from AstraZeneca, Bristol-Myers Squibb, Merck, Lilly, and other innovative life sciences organizations on key challenges impacting medical affairs and a roadmap for success in the coming decade. Sponsored by: SHYFT Analytics This whitepaper provides a snapshot of where the biopharma industry is now, where it's heading, and how companies are allocating their resources to adapt & grow. Sponsored by: IBM Watson Health IBM’s highlighted solutions reside in a security-rich cloud environment—home for capturing, managing and analyzing clinical study data with control, accuracy and confidence. These solutions lay the groundwork for further integration with IBM® Watson® cognitive technology. Sponsored by: IBM Watson Health Inpatient View and Outpatient View are powered by robust data assets and use sophisticated projection methodologies to help ensure accuracy of reporting. Sponsored by: IBM Watson Health Acknowledging various stakeholder networks, as well as recognizing variances within the regulatory environment, we believe, is essential for companies looking to uncover the right decision-makers in support of biologics or biosimilars. Learn more. Sponsored by: ON24 Discover solutions to the most common challenges faced by medical device companies. Sponsored by: Eli Lilly and Company in partnership with Xcenda Download this complimentary paper that explores the practice of step therapy and its impact on key stakeholders in the US healthcare system. Sponsored by: Clarivate Analytics 18 high-value new licensing deals worth in excess of $500 million took place during the second quarter of 2019 -Get the Q2 2019 Biopharma licensing report for full details and insights. Sponsored by: Patheon, by Thermo Fisher Scientific Is your API development on track? Sponsored by: BBK Worldwide Get the latest data on how people are using apps to manage their health, and learn how you can leverage it in the development of your next clinical trial app. Sponsored by: Blue Latitude Health Report: How to design digital services that deliver value and improve outcomes for patients, healthcare professionals and the healthcare systems they serve Sponsored by: Article Galaxy powered by Reprints Desk This white paper examines the skyrocketing cost of drug development and provides step-by-step guidance for executing a successful fail fast strategy. Sponsored by: Roche and IQVIA A global landscape study of funding trends and innovations. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. FierceBiotech Executive Breakfast at the J.P. Morgan Healthcare Conference 2020 January 14, 2020 | The Fairmont Hotel | San Francisco, CA 4th Annual Gene Therapy for Rare Disorders March 30 – April 2, 2020 | Boston, MA A Rare Affair for Rare Diseases January 12, 2020 | San Francisco, CA | 